Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142

被引：0

作者：

Van Cutsem, E. ^{[1
,2
]}

Dixon, M. ^{[3
]}

Taylor, F. ^{[4
]}

Sun, X. ^{[4
]}

Yip, C. ^{[4
]}

Blum, S. I. ^{[5
]}

机构：

[1] Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium

[2] Katholieke Univ Leuven, Leuven, Belgium

[3] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Lawrenceville, GA USA

[4] Adelphi Values LLC, Patient Centered Outcomes, Boston, MA USA

[5] Bristol Myers Squibb, WW Hlth Econ & Outcomes Res, Princeton, NJ USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.958

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

437P

引用

页码：S553 / S553

页数：1

共 50 条

[21] ONCOLOGISTS' PERCEPTIONS OF NIVOLUMAB PLUS IPILUMUMAB (NIVO plus IPI) AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC)
Emidio, O.
Iqbal, Z.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S351 - S351
[22] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW
Lenz, Heinz-Josef
Lonardi, Sara
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Manzano, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Joshi, Rohit
Cela, Elvis
Chen, Tian
Jin, Lixian
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab plus ipilimumab in CheckMate-142
Kopetz, Scott
Andre, Theirry
Overman, Michael J.
Zagonel, Vittorina
Lonardi, Sara
Aglietta, Massimo
Gelsomino, Fabio
McDermott, Ray
Wong, Ka Yeung Mark
Hendlisz, Alain
Garcia Alfonso, Pilar
Lenz, Heinz-Josef
Walsh, Alice
Moss, Rebecca A.
Greenawalt, Danielle
Cao, Z. Alexander
CANCER RESEARCH, 2018, 78 (13)
[24] Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function (LoF) Mutations in Patients with DNA Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC) Treated with Nivolumab plus Ipilimumab in CheckMate-142
Kopetz, S.
Andre, T.
Overman, M. J.
Zagonel, V.
Lonardi, S.
Aglietta, M.
Gelsomino, F.
McDermott, R.
Wong, K. Y. M.
Hendlisz, A.
Alfonso, P. G.
Lenz, H. J.
Walsh, A.
Moss, R. A.
Greenawalt, D.
Cao, Z. A.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (03): : S3 - S3
[25] Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.
Lenz, Heinz-Josef
Lonardi, Sara
Zagonel, Vittorina
Van Cutsem, Eric
Limon, Luisa M.
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Luppi, Gabriele
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
Yang Jing
Memaj, Arteid
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[26] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Andre, T.
Lonardi, S.
Lenz, H. J.
Jensen, L. H.
Van Cutsem, E.
Touchefeu, Y.
Garcia-Carbonero, R.
Tougeron, D.
Mendez, G. A.
Schenker, M.
de la Fouchardiere, C.
Limon, M. L.
Yoshino, T.
Li, J.
Manzano Mozo, J. L.
Cela, E.
Chen, T.
Lei, M.
Jin, L.
Elez Fernandez, M. E.
ANNALS OF ONCOLOGY, 2024, 35 : S451 - S452
[27] On pembrolizumab (Keytruda) in microsatellite instability-high/mismatch repair deficient (MSI-h/MMRd) metastatic colorectal cancer (mCRC)
Bekaii-Saab, Tanios S.
ONCOLOGY-NEW YORK, 2021, 35 (07): : 380 - 380
[28] Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
Overman, Michael J.
Bergamo, Francesca
McDermott, Raymond S.
Aglietta, Massimo
Chen, Franklin
Gelsomino, Fabio
Wong, Mark
Morse, Michael
Van Cutsem, Eric
Hendlisz, Alain
Neyns, Bart
Moss, Rebecca Anne
Zhao, Huanyu
Cao, Z. Alexander
Kamble, Shital
Kopetz, Scott
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[29] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, Heinz-Josef
Lonardi, Sara
Zagonel, Vittorina
Van Cutsem, Eric
Limon, M. Luisa
Wong, Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
Yang, Jing
Ledeine, Jean-Marie
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
Cohen, Romain
Bennouna, Jaafar
Henriques, Julie
Tournigand, Christophe
De La Fouchardiere, Christelle
Tougeron, David
Borg, Christophe
Mazard, Thibault
Chibaudel, Benoist
Garcia-Larnicol, Marie-Line
Svrcek, Magali
Vernerey, Dewi
Menu, Yves
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →